Cytokinetics Inc
NASDAQ:CYTK

Watchlist Manager
Cytokinetics Inc Logo
Cytokinetics Inc
NASDAQ:CYTK
Watchlist
Price: 52.02 USD 3.52% Market Closed
Market Cap: 6.1B USD
Have any thoughts about
Cytokinetics Inc?
Write Note

Cytokinetics Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cytokinetics Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Cytokinetics Inc
NASDAQ:CYTK
Income from Continuing Operations
-$576.4m
CAGR 3-Years
-36%
CAGR 5-Years
-37%
CAGR 10-Years
-43%
Abbvie Inc
NYSE:ABBV
Income from Continuing Operations
$5.1B
CAGR 3-Years
-12%
CAGR 5-Years
9%
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Income from Continuing Operations
$113m
CAGR 3-Years
-75%
CAGR 5-Years
-47%
CAGR 10-Years
-36%
Amgen Inc
NASDAQ:AMGN
Income from Continuing Operations
$4.2B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Income from Continuing Operations
-$479.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
2%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Income from Continuing Operations
$4.7B
CAGR 3-Years
-13%
CAGR 5-Years
17%
CAGR 10-Years
30%
No Stocks Found

Cytokinetics Inc
Glance View

Market Cap
6.1B USD
Industry
Biotechnology

Cytokinetics Inc., a clinical-stage biopharmaceutical company, is at the forefront of developing impactful treatments for muscle diseases, leveraging its pioneering expertise in muscle biology and discovery. Founded in 1999 and headquartered in South San Francisco, California, Cytokinetics focuses on harnessing the power of muscle function through its innovative therapies. The company’s lead product candidates, including omecamtiv mecarbil and reldesemtiv, are specifically designed to improve muscle performance in patients suffering from serious conditions like heart failure and amyotrophic lateral sclerosis (ALS). As the demand for effective treatments grows, Cytokinetics is leading the charge to enhance muscle function, aiming not just to prolong life, but to improve patients' quality of life. For investors, Cytokinetics presents a unique opportunity within the growing biopharmaceutical market. The company has strategically partnered with industry leaders, including Amgen, to accelerate the development of its therapeutic portfolio, significantly bolstering its credibility and pipeline potential. With increasing recognition of the importance of muscle health, Cytokinetics stands at an advantageous juncture, positioned to leverage its scientific know-how to unlock substantial value. As clinical trials progress and the company moves closer to potential commercialization, investors have the potential to benefit from Cytokinetics’ innovative approach to addressing unmet medical needs, making it a compelling consideration for those looking to invest in the future of healthcare innovation.

CYTK Intrinsic Value
27.1 USD
Overvaluation 48%
Intrinsic Value
Price

See Also

What is Cytokinetics Inc's Income from Continuing Operations?
Income from Continuing Operations
-576.4m USD

Based on the financial report for Sep 30, 2024, Cytokinetics Inc's Income from Continuing Operations amounts to -576.4m USD.

What is Cytokinetics Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-43%

Over the last year, the Income from Continuing Operations growth was -9%. The average annual Income from Continuing Operations growth rates for Cytokinetics Inc have been -36% over the past three years , -37% over the past five years , and -43% over the past ten years .

Back to Top